DUBLIN--(BUSINESS WIRE)--The "Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Application, By Type, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global blood plasma market size is expected to reach USD 56.92 Billion by 2030. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
Companies Mentioned
- Bayer AG
- Biotest
- CSL limited
- Fusion Health
- Grifols
- S.A
- Kedrion Biopharma
- LFB S.A
- Octa Pharma
- Sanofi
- Takeda
The active use of plasma-derived medicinal products for the treatment of rare diseases, rise in the blood collection technology, the rising geriatric population, growing demand for immunoglobulins for curing the immunodeficiency and other life-threatening diseases, and rising awareness of the blood donation are some of the major factors responsible for the driving the growth.
As per WHO, out of 250,000 individuals diagnosed to have PID (primary immune deficiencies) in the USA in 2017, roughly 125,000 get month-to-month mixtures of immunoglobulins, and it is assessed that more than 300,000 patients overall get month to month immunoglobulins implantations for PID. The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the industry.
WHO also appraises that the global population over 60 years will almost be twofold from 12% to 22% between 2015 and 2050, and approximately 80 percent of the 65+ population will be living in middle-income countries by 2040. The expansion in the maturing population around the world might trigger a spike in infections that require blood treatment. Accordingly, an ascent in the geriatric populace will assist the development of the market.
Based on the product type, the immunoglobulins fragment is estimated to be one of the biggest portions of the blood plasma industry during the forecast period. The largest share is attributed due to the primary or chronic immune deficiency, increasing their demand for improving disease treatment is fueling the industry growth. Based on the regional level, the market is assessed to rule by North America during the forecast period. Some of the elements driving the development of the North American market are the rising utilization of plasma-derived products, the presence of leading driving players, and the strategic developments made by the organizations in this region.
Market participants such as Biotest, CSL Limited, Grifols, S.A, Kedrion Biopharma, LFB S.A, Octa Pharma, Bayer AG, Sanofi, Fusion Health, and Takeda are some of the key players operating in the market. In August 2020, Kedrion Biopharma (Italy) began the improvement of a plasma-inferred treatment for treating the COVID-19 infection that could make it accessible to patients in just three to a half year. Grifols, S.A. (Spain) is gathering blood plasma for the delivery of hyper-immune globulin from recuperated COVID-19 patients for the potential treatment of Covid illness.
The publisher has segmented the blood plasma market report based on type, application, end-use, and region:
Blood Plasma, Type Outlook (Revenue - USD Billion, 2018 - 2030)
- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Hyperimmune Globulin
- Others
Blood Plasma, Application Outlook (Revenue - USD Billion, 2018 - 2030)
- Hemophilia
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Von Willebrand's Disease
- Others
Blood Plasma, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)
- Hospitals
- Clinics
- Others
Blood Plasma, Regional Outlook (Revenue - USD Billion, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Netherlands
- Russia
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
For more information about this report visit https://www.researchandmarkets.com/r/dphd3s
